Local EMS Develops DIY EpiPen Alternative for $25
With the continuing controversy over the skyrocketing price of the life-saving EpiPen device, one local EMS developed their own Epi Kit as a cost-saving yet effective alternative. King County EMS James Duren weighed in on how the kit got its start.
Local EMS cuts costs with alternative to pricey EpiPen
From EpiPen to Epi Kit
What's On Our Radar: Wednesday, September 21st, 2016
Today’s the day!
Lawmakers to Grill Mylan CEO, Calls For EpiPen Oversight Probe
Mylan faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company’s rebates to government healthcare plans
Suriname slides into economic abyss, in shadow of Venezuela
It is a South American nation in crisis: Businesses are closing, food prices are soaring and hospitals are running out of basic supplies such as paper towels and bandages.
Samsung says replacements available for recalled Note 7
Samsung says new Galaxy Note 7 smartphones will be available in U.S. stores starting Wednesday to replace about 1 million devices that are being recalled because of a problem with batteries catching fire.
The ABC's of Medicare for Seniors, Caregivers
This week is National Medicare Education Week. And with open enrollment just around the corner, there is no better time to review the ABC’s of Medicare.
Feds preview rules of the road for self-driving cars
Obama administration officials previewed long-awaited guidance Monday that attempts to bring self-driving cars to the nation's roadways safely — without creating so many roadblocks that the technology can't make it to market quickly.
GSK names Emma Walmsley as new chief executive
Drugmaker GlaxoSmithKline says Emma Walmsley will be the company's new chief executive, replacing Andrew Witty when he retires next March.
GlaxoSmithKline Names Walmsley New CEO
GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates.
FDA tentatively approves first drug for muscular dystrophy
Federal health regulators have granted tentative approval to a highly contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
Samsung phones reportedly catch fire in China
Two Samsung Galaxy Note 7 smartphones reportedly have caught fire in China in what, if confirmed, would be the first such incidents in that country.
WebMD CEO Departs By 'Mutual Agreement'
David Schlanger is out as chief executive at WebMD Health Corp., the company said Monday, after a three-year stint leading the health-care advice website.
Insider Q&A: Why so little relief on pricey biologic drugs
Drugs made from living cells, instead of by mixing chemicals, have brought major advances since the late 1990s to the treatment of various cancers, immune system disorders, growth hormone deficiency and eye diseases.
FCA recalling 1.9 million vehicles for air bag defect
Fiat Chrysler Automobiles is recalling more than 1.9 million vehicles worldwide because their air bags might not deploy in a crash.
US regulators: Official recall of 1M Samsung Note 7 phones
U.S. safety regulators announced a formal recall of Samsung's Galaxy Note 7 smartphone Thursday after a spate of fires led to injuries and property damage — along with a global marketing headache for the South Korean tech giant.
Oregon settles lawsuit for botched health care rollout
Oregon settled with a California software giant in a lawsuit that accused Oracle America Inc. of collecting tens of millions of dollars to create a state health care exchange website that didn't work.
WADA confirms another hacking of its athletes database
Three-time Tour de France winner Chris Froome has "no issue" with his medical data being leaked, in an alleged criminal attack by Russian hackers on a World Anti-Doping Agency database.
What to do to if you own a Samsung Galaxy Note 7
Do you have a Galaxy Note 7 that was the subject of an official recall Thursday? Here's what to do if you own one of Samsung's new smartphones.
Bayer-Monsanto's $66B Deal Roils Regulators and Now Politicians
Bayer AG’s $66 billion purchase of Monsanto (NYSE:MON) is facing a nearly unprecedented wall of regulatory and political scrutiny that investors and analysts believe will eventually kill the biggest merger of 2016, the FOX Business Network has learned.















